Pharma BD Deal Intelligence
Sangamo BioSciences Inc. / Gendaq Limited (UK)
2001 · Acquisition/Merger · $40M · Complete
Announcement Sentiment
83
Strongly positive
Below $250M but strategically notable: zinc-finger nuclease IP consolidation — foundational for Sangamo's ZFN gene-editing platform.
Key facts
- Announced Jul 06, 2001
- Deal value $40M
- Deal type Acquisition/Merger
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals